Free Trial
NASDAQ:KYTX

Kyverna Therapeutics (KYTX) Stock Price, News & Analysis

Kyverna Therapeutics logo
$2.90 +0.07 (+2.30%)
Closing price 07/3/2025 02:21 PM Eastern
Extended Trading
$2.84 -0.05 (-1.73%)
As of 07/3/2025 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Kyverna Therapeutics Stock (NASDAQ:KYTX)

Key Stats

Today's Range
$2.76
$2.97
50-Day Range
$2.02
$3.60
52-Week Range
$1.78
$11.40
Volume
537,924 shs
Average Volume
384,241 shs
Market Capitalization
$125.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.50
Consensus Rating
Buy

Company Overview

Kyverna Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
25th Percentile Overall Score

KYTX MarketRank™: 

Kyverna Therapeutics scored higher than 25% of companies evaluated by MarketBeat, and ranked 716th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Kyverna Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Kyverna Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Kyverna Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Kyverna Therapeutics are expected to decrease in the coming year, from ($3.29) to ($3.73) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Kyverna Therapeutics is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Kyverna Therapeutics is -0.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Kyverna Therapeutics has a P/B Ratio of 0.47. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Kyverna Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    10.79% of the float of Kyverna Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Kyverna Therapeutics has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in Kyverna Therapeutics has recently increased by 0.48%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Kyverna Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Kyverna Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.79% of the float of Kyverna Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Kyverna Therapeutics has a short interest ratio ("days to cover") of 6.3.
  • Change versus previous month

    Short interest in Kyverna Therapeutics has recently increased by 0.48%, indicating that investor sentiment is decreasing.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Kyverna Therapeutics this week, compared to 7 articles on an average week.
  • Search Interest

    Only 1 people have searched for KYTX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Kyverna Therapeutics to their MarketBeat watchlist in the last 30 days.
Receive KYTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kyverna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KYTX Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
3 Promising Penny Stocks With Market Caps Over $100M
See More Headlines

KYTX Stock Analysis - Frequently Asked Questions

Kyverna Therapeutics' stock was trading at $3.74 at the beginning of 2025. Since then, KYTX shares have decreased by 22.6% and is now trading at $2.8950.

Kyverna Therapeutics, Inc. (NASDAQ:KYTX) issued its earnings results on Tuesday, May, 13th. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.21) by $0.18.

Kyverna Therapeutics (KYTX) raised $319 million in an IPO on Thursday, February 8th 2024. The company issued 14,500,000 shares at a price of $22.00 per share.

Kyverna Therapeutics' top institutional investors include Kera Capital Partners Inc. (0.98%).
View institutional ownership trends
.

Shares of KYTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kyverna Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/13/2025
Today
7/06/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KYTX
Previous Symbol
NASDAQ:KYTX
Fax
N/A
Employees
96
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.50
High Stock Price Target
$33.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+539.0%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$127.48 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$7.03 million
Price / Cash Flow
N/A
Book Value
$6.17 per share
Price / Book
0.47

Miscellaneous

Free Float
N/A
Market Cap
$125.12 million
Optionable
Optionable
Beta
2.95
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:KYTX) was last updated on 7/7/2025 by MarketBeat.com Staff
From Our Partners